Telix Pharmaceuticals (TLX) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 group revenue reached US$230 million, an 11% increase quarter-over-quarter and 24% year-over-year, driven by strong growth in Precision Medicine and TMS segments.

• Precision Medicine revenue rose 16% sequentially, with robust uptake of Illuccix and Gozellix, and U.S. dose volumes up 5% quarter-over-quarter.

• Therapeutics pipeline advanced with key clinical milestones, including positive safety results in the ProstACT Phase 3 trial and regulatory progress for TLX101-Px and TLX591-Px.

Financial highlights

• Group revenue for Q1 2026 was US$230 million, up 11% from Q4 2025 and 24% from Q1 2025.

• Precision Medicine revenue was US$186 million, up 16% sequentially and 23% year-over-year.

• TMS third-party revenue was US$44 million, up 29% year-over-year.

Outlook and guidance

• FY 2026 revenue guidance reaffirmed at US$950 million to US$970 million, reflecting continued commercial momentum and full-year RLS contribution.

• R&D expenditure guidance for FY 2026 remains at US$200 million to US$240 million, subject to commercial milestones.